TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30936830

Group type: EXPERIMENTAL
Intervention: Single dose of Ticagrelor, dosage not specified, duration not specified
Number of subjects: 0
Study: 30937138

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) drops containing tree pollen allergens (ORALVAC) with a rapid home-based up-dosing schedule
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) drops containing tree pollen allergens (ORALVAC)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Pre-seasonal treatment initiation with SLIT
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (previously established schedules of SLIT)
Number of subjects: 164
Study: 30937156

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (three small-group sessions over 6 months)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study: 30937345

Group type: EXPERIMENTAL
Intervention: Probiotic product (Lactoflorene)
Number of subjects: 0
Study: 30937394

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 1064
Study: 30937421

Group type: EXPERIMENTAL
Intervention: SHINE intervention promoting early initiation (EI) and exclusive breastfeeding (EBF) delivered by village health workers.
Number of subjects: 0
Study: 30937580

Group type: EXPERIMENTAL
Intervention: DHA (highest tertile)
Number of subjects: 3049

Group type: EXPERIMENTAL
Intervention: EPA (highest tertile)
Number of subjects: 3049

Group type: EXPERIMENTAL
Intervention: DHA + EPA (highest tertile)
Number of subjects: 3049

Group type: EXPERIMENTAL
Intervention: Total n-3 PUFAs (highest tertile)
Number of subjects: 3049
Study: 30937889

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 0
Study: 30937899

Group type: EXPERIMENTAL
Intervention: Homozygous for MC3R C17A + G241A haplotype
Number of subjects: 237

Group type: COMPARATOR
Intervention: Heterozygous and wild-type participants
Number of subjects: 237
Study: 30938420

Group type: EXPERIMENTAL
Intervention: Cardiac phenotype (n'=210)
Number of subjects: 1411

Group type: EXPERIMENTAL
Intervention: Cardiac mutations or ATTRwt
Number of subjects: 1411
Study: 30938626

Group type: EXPERIMENTAL
Intervention: Early DISH criteria
Number of subjects: 3634

Group type: EXPERIMENTAL
Intervention: Interrater reliability
Number of subjects: 3634

Group type: EXPERIMENTAL
Intervention: Intrarater reliability
Number of subjects: 3634
Study: 30938645

Group type: COMPARATOR
Intervention: Placebo control (tonic water)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: SDF solution
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: SDF solution followed by potassium iodide (KI) solution
Number of subjects: 323
Study: 30938687

Group type: EXPERIMENTAL
Intervention: Health Coaching (HC) with 8 sessions over a 5-month period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (including education about DD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 0
Study: 30938688

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response and Text Message (IVR-T) intervention including automated text messages or phone calls in English or Spanish, reminders for appointments, medication refills, and motivational messages; offered home blood pressure monitor.
Number of subjects: 295

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 295
Study: 30938714

Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy followed by CD19-targeted CAR T-cells (19-28z).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ibrutinib therapy at the time of autologous T-cell collection and/or CAR T-cell administration.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy and 19-28z CAR T-cells.
Number of subjects: 20
Study: 30938796

Group type: EXPERIMENTAL
Intervention: Amyloid PET
Number of subjects: 16008
Study: 30938874

Group type: EXPERIMENTAL
Intervention: Congenital heart disease (CHD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depressive symptoms, self-esteem level, and types of treatment received
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy counterparts (control group)
Number of subjects: 0
Study: 30939086

Group type: EXPERIMENTAL
Intervention: Hypnosis-based group intervention combining self-care and hypnosis; details on dosage and duration not available.
Number of subjects: 0
Study: 30939136

Group type: EXPERIMENTAL
Intervention: Rifampin (RIF)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Linezolid (LZD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MFX)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clofazimine (CFZ)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Kanamycin (KAN)
Number of subjects: 15
Study: 30939290

Group type: EXPERIMENTAL
Intervention: Latinos
Number of subjects: 402

Group type: COMPARATOR
Intervention: Non-Latino Whites (NLWs)
Number of subjects: 402
Study: 30939488

Group type: EXPERIMENTAL
Intervention: Sarcopenia group (defined by sex-specific TPMT/height cutoff)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Nonsarcopenia group (defined by sex-specific TPMT/height cutoff)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Sarcopenia group
Number of subjects: 186
Study: 30939489

Group type: EXPERIMENTAL
Intervention: EBR 50 mg plus GZR 50 mg once daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: EBR 50 mg plus GZR 100 mg once daily for 12 weeks (control group)
Number of subjects: 30
Study: 30939908

Group type: EXPERIMENTAL
Intervention: WATCHMAN left atrial appendage occlusion device
Number of subjects: 1020
Study: 30940123

Group type: EXPERIMENTAL
Intervention: Routine TB examination (clinical evaluation, sputum smear microscopy, chest radiography)
Number of subjects: 360
Study: 30940149

Group type: EXPERIMENTAL
Intervention: Option B+
Number of subjects: 50
Study: 30940206

Group type: EXPERIMENTAL
Intervention: Facebook intervention posts tailored to readiness to quit smoking (N=180) in the Ready group.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Facebook intervention posts tailored to readiness to quit smoking (N=180) in the Not Ready group.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Overall STAND intervention rating.
Number of subjects: 29
Study: 30940215

Group type: EXPERIMENTAL
Intervention: Standardised meal
Number of subjects: 22
Study: 30940762

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour intervention (Sit-Less and Move-More stages) over 22 weeks (15-week intervention + 7-week follow-up) with individual coaching and a Fitbit for monitoring activity.
Number of subjects: 40
Study: 30940770

Group type: EXPERIMENTAL
Intervention: Prednisolone (0.5 mg/kg for 7 days)
Number of subjects: 44
Study: 30940999

Group type: EXPERIMENTAL
Intervention: Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine
Number of subjects: 672
Study: 30941094

Group type: EXPERIMENTAL
Intervention: Apomorphine, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30941095

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) intramuscular injections
Number of subjects: 0
Study: 30941307

Group type: EXPERIMENTAL
Intervention: Ribociclib and Cetuximab
Number of subjects: 0
Study: 30941340

Group type: EXPERIMENTAL
Intervention: Previous light-active physical activity at work
Number of subjects: 0
Study: 30941702

Group type: EXPERIMENTAL
Intervention: Surgical specialties (SS)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Non-surgical specialties (NSS)
Number of subjects: 190
Study: 30942111

Group type: EXPERIMENTAL
Intervention: Drug adherence assessment via toxicological urine analysis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Repeated urine analysis over a time range of up to 17 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Single time point urine analysis
Number of subjects: 18
Study: 30942148

Group type: EXPERIMENTAL
Intervention: Contegra 12 mm
Number of subjects: 53

Group type: COMPARATOR
Intervention: Pulmonary homograft
Number of subjects: 53
Study: 30942698

Group type: EXPERIMENTAL
Intervention: Mobile EMA tool with auditory alerts (3 alerts at 10-min intervals)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Mobile EMA tool without auditory alerts
Number of subjects: 59
Study: 30942881

Group type: EXPERIMENTAL
Intervention: TFV-DP <800 fmol/punch
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: TFV-DP 800 to <1650 fmol/punch
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: TFV-DP <800 fmol/punch (virologically suppressed)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: TFV-DP 800 to <1650 fmol/punch (virologically suppressed)
Number of subjects: 451
Study: 30943079

Group type: EXPERIMENTAL
Intervention: ACLR group
Number of subjects: 156

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Single-legged drop jump
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: CoD tests
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Single-legged hop for distance
Number of subjects: 156
Study: 30943123

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) at 12.0 Gy/fraction (fx)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) at 11.5 Gy/fx
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) at 12.0 Gy/fx
Number of subjects: 120
Study: 30943124

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician or patient decision.
Number of subjects: 98
Study: 30943769

Group type: EXPERIMENTAL
Intervention: Fontan patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 10
Study: 30943782

Group type: EXPERIMENTAL
Intervention: Daily use of shoes equipped with the foot compression device (Footbeat™, AVEX, Grand Junction, CO, USA) for 4 weeks
Number of subjects: 0
Study: 30943843

Group type: EXPERIMENTAL
Intervention: Cancer screening intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study: 30943913

Group type: EXPERIMENTAL
Intervention: Serum klotho levels in patients with metabolic syndrome (MS)
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: Serum klotho levels
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: Serum klotho levels < 518 pg/mL
Number of subjects: 1754
Study: 30943928

Group type: EXPERIMENTAL
Intervention: Circulating tumor cell (CTC) detection before therapy and after one course of preoperative FOLFOX
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Baseline CTC detection
Number of subjects: 36
Study: 30943979

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Conventional risk factors and other markers (high-sensitivity C-reactive protein, pulse wave analysis, heart rate variability)
Number of subjects: 522
Study: 30943998

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 59
Study: 30944020

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) chemo monotherapy regimens (cetuximab, docetaxel, or methotrexate)
Number of subjects: 0
Study: 30944151

Group type: EXPERIMENTAL
Intervention: Personalised 3D-engineered stents
Number of subjects: 10
Study: 30944585

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 1461
Study: 30944736

Group type: EXPERIMENTAL
Intervention: High engagement with messaging
Number of subjects: 201

Group type: COMPARATOR
Intervention: Self-tracking
Number of subjects: 201
Study: 30944763

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy with D2 lymph node dissection (LND)
Number of subjects: 157
Study: 30945522

Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Aegean and Mediterranean regions
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Black Sea, Southeast, and East Anatolia regions
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Mediterranean and Southeast Anatolia regions
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Southeast Anatolia
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Mediterranean, Southeast Anatolia, and Black Sea regions
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from East Anatolia
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Heart failure and preserved ejection fraction patients from Black Sea region
Number of subjects: 819
Study: 30945607

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30945636

Group type: EXPERIMENTAL
Intervention: HeartWare centrifugal-flow ventricular assist device (HVAD) implantation via thoracotomy approach
Number of subjects: 144
Study: 30946021

Group type: EXPERIMENTAL
Intervention: HeartHab app
Number of subjects: 32
Study: 30946022

Group type: EXPERIMENTAL
Intervention: Coach-facilitated digital cognitive behavioral program
Number of subjects: 593

Group type: COMPARATOR
Intervention: Control group (CAU)
Number of subjects: 593
Study: 30946162

Group type: EXPERIMENTAL
Intervention: HIV-infected smokers
Number of subjects: 330

Group type: COMPARATOR
Intervention: HIV-uninfected smokers
Number of subjects: 330
Study: 30946294

Group type: EXPERIMENTAL
Intervention: Current practices involving consultation of multiple rehabilitation services for each case example provided.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Interest in developing and implementing guidelines for PICU-based rehabilitation.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Need for additional research evidence.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Barriers to implementation of PICU-based rehabilitation.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Assessment of long-term functional outcomes of PICU patients.
Number of subjects: 148
Study: 30946553

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (4 weeks post-transplant)
Number of subjects: 44

Group type: COMPARATOR
Intervention: HCV-infected lung-transplant recipients
Number of subjects: 44
Study: 30946917

Group type: EXPERIMENTAL
Intervention: Newborn SCID screening using quantification of T-cell receptor excision circles (TRECs) on Guthrie cards
Number of subjects: 190517

Group type: COMPARATOR
Intervention: Control group (no SCID screening)
Number of subjects: 190517

Group type: EXPERIMENTAL
Intervention: Cost of screening
Number of subjects: 190517

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 190517
Study: 30946996

Group type: EXPERIMENTAL
Intervention: Permacol™ intervention for CAWHR repair
Number of subjects: 77
Study: 30947300

Group type: EXPERIMENTAL
Intervention: Surgery for DCM
Number of subjects: 757
Study: 30947753

Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: IDSA/ATS minor criteria
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: SCAP
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: Age, sex, and pack-years
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: Antibiosis before hospitalization
Number of subjects: 1532
Study: 30947942

Group type: EXPERIMENTAL
Intervention: CENTERA transcatheter heart valve (THV)
Number of subjects: 203
Study: 30948185

Group type: EXPERIMENTAL
Intervention: Cryoballoon pulmonary vein isolation (CB-PVI)
Number of subjects: 460
Study: 30948361

Group type: EXPERIMENTAL
Intervention: High socioeconomic status (SES)
Number of subjects: 1259

Group type: COMPARATOR
Intervention: Low socioeconomic status (SES)
Number of subjects: 1259
Study: 30948562

Group type: EXPERIMENTAL
Intervention: Radiomics model for prediction of adverse motor outcomes
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant and Toddler Development-III (Bayley-III)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Bayley-III and Gross Motor Function Classification System
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Multiple-modelling methodology
Number of subjects: 394
Study: 30948594

Group type: EXPERIMENTAL
Intervention: Capillary lactate measured by CL-Scout+
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Capillary lactate measured by CL-Nova
Number of subjects: 240

Group type: COMPARATOR
Intervention: Venous lactate measured by VL-Scout+
Number of subjects: 240

Group type: COMPARATOR
Intervention: Venous lactate measured by VL-Nova
Number of subjects: 240
Study: 30948618

Group type: EXPERIMENTAL
Intervention: Colli-Pee device for home urine collection
Number of subjects: 213

Group type: COMPARATOR
Intervention: Routine clinic-based urine collection
Number of subjects: 213
Study: 30949218

Group type: EXPERIMENTAL
Intervention: Shensong Yangxin (SSYX)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study: 30949435

Group type: EXPERIMENTAL
Intervention: Guided internet-delivered individually-tailored ACT-influenced cognitive behavioural intervention (iNNOVBC) for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) in a waiting list control group (WLC)
Number of subjects: 0
Study: 30949667

Group type: EXPERIMENTAL
Intervention: Alcoholic beverages (each extra serving per day)
Number of subjects: 1966

Group type: EXPERIMENTAL
Intervention: Milk (replacement of 5 En% of alcoholic beverages)
Number of subjects: 1966

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (replacement of 5 En% of alcoholic beverages)
Number of subjects: 1966
Study: 30949674

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals treatment
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Registry follow-up
Number of subjects: 242

Group type: COMPARATOR
Intervention: Cirrhosis status
Number of subjects: 242
Study: 30949906

Group type: EXPERIMENTAL
Intervention: Mealtime faster aspart with carbohydrate counting
Number of subjects: 2168

Group type: COMPARATOR
Intervention: Insulin aspart (IAsp)
Number of subjects: 2168

Group type: EXPERIMENTAL
Intervention: Both treatments (mealtime faster aspart and IAsp)
Number of subjects: 2168
Study: 30949907

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30950636

Group type: EXPERIMENTAL
Intervention: Pirfenidone treatment, timing of treatment initiation not specified.
Number of subjects: 0
Study: 30950802

Group type: EXPERIMENTAL
Intervention: Web version of the intervention (HŞKA)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Mobile app of the intervention with automated supportive SMS based on PST
Number of subjects: 444

Group type: COMPARATOR
Intervention: Waiting control group (access to intervention after 4 months)
Number of subjects: 444
Study: 30951600

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus an optimized background regimen
Number of subjects: 23
Study: 30951840

Group type: EXPERIMENTAL
Intervention: One-time infusion of donor-derived cytokine-induced killer (CIK) cells at a dose of 1 × 10^6 cells/kg.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-myeloablative conditioning with total lymphoid irradiation and antithymocyte globulin (TLI-ATG).
Number of subjects: 0
Study: 30952488

Group type: EXPERIMENTAL
Intervention: Hydroxyurea 20 mg/kg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard care protocol
Number of subjects: 29
Study: 30952529

Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy (LVH) identified by LV mass index >46.7 g/m
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Presence of LVH
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: LVH
Number of subjects: 132
Study: 30952559

Group type: EXPERIMENTAL
Intervention: Automated quantitative analysis of MRI using artificial neural networks (ANN)
Number of subjects: 455
Study: 30952619

Group type: EXPERIMENTAL
Intervention: Chemoradiation (87% of patients)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Presence of PIK3CA alterations (40%)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Presence of KMT2D (15%) and KMT2C (16%) alterations
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Loss-of-function mutations in epigenetic modulator genes (47%)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: TLR4 gene amplifications (10%)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) gene alterations (7%)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: RPPA protein expression analysis
Number of subjects: 419
Study: 30952640

Group type: EXPERIMENTAL
Intervention: Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone (KDD)
Number of subjects: 23
Study: 30952998

Group type: EXPERIMENTAL
Intervention: Vimentin over-expressing cells
Number of subjects: 192

Group type: COMPARATOR
Intervention: Vimentin lacking cells
Number of subjects: 192

Group type: COMPARATOR
Intervention: Serum Vimentin levels in patients with sepsis
Number of subjects: 192

Group type: COMPARATOR
Intervention: Vimentin expression in lymphocytes from septic patients
Number of subjects: 192

Group type: COMPARATOR
Intervention: Serum Vimentin levels in nonsurvivor group
Number of subjects: 192
Study: 30953061

Group type: EXPERIMENTAL
Intervention: Intranasal challenge with influenza A(H1N1)pdm09 virus
Number of subjects: 7
Study: 30953148

Group type: EXPERIMENTAL
Intervention: Urinary equol (measured by high-performance liquid chromatography-tandem mass spectrometry)
Number of subjects: 2818

Group type: EXPERIMENTAL
Intervention: Urinary equol (men)
Number of subjects: 2818

Group type: EXPERIMENTAL
Intervention: Urinary equol (women)
Number of subjects: 2818

Group type: EXPERIMENTAL
Intervention: Urinary equol (third tertile)
Number of subjects: 2818

Group type: EXPERIMENTAL
Intervention: hsCRP and RBP4
Number of subjects: 2818
Study: 30953238

Group type: EXPERIMENTAL
Intervention: Afatinib (20, 30, 40, or 50 mg/day; physician decision)
Number of subjects: 1602
Study: 30953533

Group type: EXPERIMENTAL
Intervention: RPV-based regimen after switching from NNRTI or boosted PI
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: RPV-based regimen
Number of subjects: 320